Cargando…
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
Oral nirmatrelvir plus ritonavir (Paxlovid(™)) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nirmatrelvir inhibits the main protease of SARS-CoV-2, with ritonavir acting as a pharmacokinet...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734504/ https://www.ncbi.nlm.nih.gov/pubmed/36532315 http://dx.doi.org/10.1007/s40267-022-00971-1 |